Samidorphan-d5

• Description :

  Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo[1][2][3][4].

• Product Name Alternative :

  ALKS-33-d5; RDC-0313-d5

• UNSPSC :

  12352005

• Target :

  Isotope-Labeled Compounds; Opioid Receptor

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling; Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Purity :

  90.0

• Smiles :

  O=C(N)C1=CC([2H])=C(C[C@H]([C@@]2(CC3([2H])[2H])O)N(CC4)CC5CC5)C([C@]42C([2H])([2H])C3=O)=C1O

• Molecular Formula :

  C21H21D5N2O4

• Molecular Weight :

  375.47

• References & Citations :

  [1]Russak, et sl. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Annals of Pharmacotherapy 53.2 (2019) : 211-236.|[2]McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46 (3) :239-45.|[3]Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2) :S366.|[4]Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond) . 2022 Jun 30;79:104115.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  δ Opioid Receptor/DOR; κ Opioid Receptor/KOR; μ Opioid Receptor/MOR